Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments
Pediatric Blood & Cancer2013Vol. 61(2), pp. 238–244
Citations Over TimeTop 10% of 2013 papers
Pete Anderson, Paul A. Meyers, Eugenie S. Kleinerman, Karthik Venkatakrishnan, Dennis P.M. Hughes, Cynthia E. Herzog, Winston W. Huh, Robert M. Sutphin, Yatin M. Vyas, Violet Shen, Anne B. Warwick, Nicholas D. Yeager, Cristina Oliva, B. Wang, Y. Liu, Alexander J. Chou
Abstract
Mifamurtide had a manageable safety profile; PK/PD of mifamurtide in this patient access study was consistent with prior studies. Two-year OS was 45.9%. A randomized clinical trial would be required to definitively determine impact on patient outcomes.
Related Papers
- → The degree of chills for risk of bacteremia in acute febrile illness(2005)84 cited
- → High positivity of blood cultures obtained within two hours after shaking chills(2018)17 cited
- → The study on the syndrome of Sosihotang's alternate chills and fever in Sang Han Lun(2014)1 cited
- → CHILDBIRTH CHILLS ARE THEY AN IMMUNOLOGICAL REACTION ?(1967)5 cited
- 『상한론(傷寒論)』 소시호탕증(小柴胡湯證)의 한열왕래(寒熱往來)에 대한 연구(硏究)(2014)